• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Merck & Co (NY:MRK)

    112.16 +2.98 (+2.73%)
    Official Closing Price Updated: 7:00 PM EDT, May 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 11,953,721
    Open 112.33
    Bid (Size) 111.72 (100)
    Ask (Size) 112.39 (400)
    Prev. Close 109.18
    Today's Range 111.88 - 114.54
    52wk Range 73.31 - 125.14
    Shares Outstanding 2,531,374,696
    Dividend Yield 3.03%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    What's going on in today's pre-market session: S&P500 movers ↗
    Via Chartmill
    News headline image
    MRK Q1 Deep Dive: Oncology Strength, New Launches, and Pipeline Milestones Define Quarter
    Global pharmaceutical company Merck (NYSE:MRK) announced better-than-expected revenue in Q1 CY2026, with sales up 4.9% year on year to $16.29 billion. The co... 
    Via StockStory

    Performance

    YTD
    +5.4%
    +5.4%
    1 Month
    -6.8%
    -6.8%
    3 Month
    +3.5%
    +3.5%
    6 Month
    +30.0%
    +30.0%
    1 Year
    +31.6%
    +31.6%

    More News

    Read More
    Top S&P500 movers in Thursday's after hours session ↗
    Via Chartmill
    News headline image
    Merck (MRK) Q1 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    Merck (NYSE:MRK) Q1 2026 Results Show Underlying Strength Despite Acquisition-Driven Loss ↗
    Via Chartmill
    News headline image
    Merck (NYSE:MRK) Surprises With Q1 CY2026 Sales
    Via StockStory
    News headline image
    Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck (MRK) Q1 Earnings Report Preview: What To Look For
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    Merck’s Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called “Bad” Cholesterol, and How It May Impact the Risk of Heart Attack or Stroke
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    3 Biotech Stocks That Could Benefit from the Patent Cliff ↗
    Via MarketBeat
    Topics Intellectual Property
    News headline image
    Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Q4 Earnings Roundup: Merck (NYSE:MRK) And The Rest Of The Branded Pharmaceuticals Segment
    Via StockStory
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Why Merck (MRK) Shares Are Trading Lower Today
    Via StockStory
    Topics Government Intellectual Property
    Which S&P500 stocks are gapping on Tuesday? ↗
    Via Chartmill
    News headline image
    3 Reasons We Love Merck (MRK)
    Via StockStory
    Topics Stocks Supply Chain
    News headline image
    Better Pharma Dividend Stock: Novartis vs. Merck ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Tech Powerhouse: S&P 500 Eyes 12.6% Growth as AI Revolution Enters Second Gear
    Via MarketMinute
    Topics Artificial Intelligence Earnings Economy
    News headline image
    The RAS Revolution: A Deep Dive into Revolution Medicines’ Path to Dominance (2026 Report)
    Via Finterra
    Topics Economy Initial Public Offering Intellectual Property
    News headline image
    1 Profitable Stock for Long-Term Investors and 2 Facing Challenges
    Via StockStory
    News headline image
    The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026
    Via Finterra
    Topics Earnings Economy Intellectual Property
    News headline image
    Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy
    From Daiichi Sankyo
    Via Business Wire
    News headline image
    1 Momentum Stock on Our Buy List and 2 We Question
    Via StockStory
    News headline image
    Which Dividend Pharma Stock Should a Value Investor Choose Today? ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Gilead Sciences Solidifies Oncology Future with $5 Billion Acquisition of ADC Innovator Tubulis
    Via MarketMinute
    Topics Bonds
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Terns Therapeutics, Inc. (Nasdaq – TERN), Whitestone REIT (NYSE – WSR), Rallybio Corporation (Nasdaq – RLYB), Day One Biopharmaceuticals, Inc. (Nasdaq - DAWN)
    From Brodsky & Smith LLC
    Via GlobeNewswire

    Frequently Asked Questions

    Is Merck & Co publicly traded?
    Yes, Merck & Co is publicly traded.
    What exchange does Merck & Co trade on?
    Merck & Co trades on the New York Stock Exchange
    What is the ticker symbol for Merck & Co?
    The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
    What is the current price of Merck & Co?
    The current price of Merck & Co is 112.16
    When was Merck & Co last traded?
    The last trade of Merck & Co was at 05/01/26 07:00 PM ET
    What is the market capitalization of Merck & Co?
    The market capitalization of Merck & Co is 283.92B
    How many shares of Merck & Co are outstanding?
    Merck & Co has 284B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.